Novo Nordisk A/S
DEEURNovo Nordisk A/S (LSE:0QIU) — Biotechnology: Pharmaceutical Preparations. Antal børser, hvor selskabets aktier handles: 3. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
- Novo Nordisk A/S — NOVO-B · CO DK Registreringsnummer ukendt
Om Virksomheden
- Websted
- novonordisk.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hovedkontor
- BAGSVAERD DENMARK, Denmark
- Administrerende Direktør
- Maziar Mike Doustdar
- Ansatte
- 66 700
- Udestående Aktier
- 3.34 mia.
- Free Float
- 3.17 mia.
- Markedsværdi
- 150.93 mia. EUR
- Insidere
- 5.27%
- Institutionelle Investorer
- 33.78%
- Branche (SIC)
- Pharmaceutical Preparations
- Juridisk Form
- ZRPO
- ISIN
- DK0060534915
- LEI
- 549300DAQ1CVT6CXN342
- Udbetalingsgrad
- 50.5%
- FCF
- 59.0 mia. DKK
- Udbetaling / FCF
- 88%
- Gæld
- 143 mia. DKK2.0 år FCF
- Udbyttestreak
- 24 år
- Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 31.12.2025 (selskabets seneste rapport).
Beskrivelse
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Udbytte
Novo Nordisk A/S (NOV) udbetaler udbytte to gange om året. Pr. År (12 måneder op til og med den senest annoncerede betaling): 1.5636 EUR pr. Aktie (betalinger: 2). Det svarer til cirka 4.71% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 01.01.2027. Uafbrudt udbyttehistorik: 24 år.
| Ex-Dato | Udbetaling | Beløb | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-08-14 | 2026-08-18 | 0.5012 EUR | 1.5/4.7 % | halvårlig | XETRA:NOV |
| 2026-03-27 | — | 1.0624 EUR | 3.2/3.2 % | halvårlig | XETRA:NOV |
Største Ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vang… | 1.38% | 46.88 mio. | 2026-07-31 |
| EuroPacific Growth Fund-… | 1.07% | 36.2 mio. | 2026-06-30 |
| VANGUARD TAX-MANAGED FUN… | 0.92% | 31.13 mio. | 2026-06-30 |
| Capital World Growth & I… | 0.77% | 26.02 mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.71% | 24.13 mio. | 2026-08-31 |
| Income Fund of America | 0.52% | 17.78 mio. | 2026-07-31 |
| Dodge & Cox Funds-Dodge… | 0.39% | 13.1 mio. | 2026-06-30 |
| Fidelity Concord Street… | 0.37% | 12.52 mio. | 2026-07-31 |
| iShares Trust-iShares MS… | 0.34% | 11.48 mio. | 2026-08-31 |
| Capital Income Builder | 0.3% | 10.32 mio. | 2026-07-31 |
| Cygnus Capital Advisors,… | 0% | 78 800 | 2026-06-30 |
| Generali Investments Cee… | 0% | 27 399 | 2026-06-30 |
| Pacer Advisors, Inc. | 0% | 24 410 | 2026-06-30 |
| Atlas Capital Advisors I… | 0% | 5 218 | 2026-06-30 |
| Novo Holdings | — | — | — |
| Novo Nordisk Foundation | — | — | — |
